BACKGROUND
VYC-12 is a novel hyaluronic acid–based dermal filler designed to treat fine lines and improve skin quality. A specialist digital camera and proprietary Digital Analysis of the Cutaneous Surface (DACS) software have previously been used to objectively measure changes in skin features.
OBJECTIVE
To assess the effect of facial treatment with VYC-12 on skin texture using the specialist camera.
MATERIALS AND METHODS
This was a prospective, open-label, 2-center study of 40 women aged 35 to 60 years treated with multiple, microdepot intradermal injections of VYC-12 (2 mL in the face; 1 mL in the neck if required). Eight patients (20.0%) required a touch-up at Day 45. Images were acquired using the specialist camera at baseline and 45 days and 6 months after treatment, and were analyzed by DACS. Clinical improvements were also assessed subjectively using the Global Aesthetic Improvement Scale (GAIS).
RESULTS
VYC-12 improved skin texture from baseline after 45 days (mean improvement: 25.9% ± 9.2%) and 6 months (mean improvement: 30.7% ± 18.2%). Improvements were also evident using the GAIS. There were no major adverse events.
CONCLUSIONS
VYC-12 improves skin quality, as measured using an objective, fast, and reproducible measuring tool. VYC-12 represents a valuable addition to the treatment armamentarium.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
Background: Treatment with Onabotulinum toxin A for the improvement of glabellar lines and crow's feet represents one of the most requested and performed procedures in the field of aesthetic medicine. The efficacy of Onabotulinumtoxin A for the treatment of glabellar lines and crow's feet have been widely reported. Although, the assessment of the grade of efficacy is actually based on clinical evaluation scales by an healthcare professional, giving space to a wide interpretative subjectivity which depends on different factors including a personal experience and a subjective aesthetic judgment.Objectives: This study aims to provide a digital evaluation tool in order to assess an objective measure of the degree of improvement for the areas treated with Onabotulinum toxin A, using a digital analysis of the images from the treated areas in order to exclude the subjective component during the evaluation.Methods: A total of 20 women with moderate-to-severe CFL and GL (maximum contraction) were enrolled in the study. Each woman received a total of 44 U of Onabotulinum toxin A (20 U and 24 U for the treatment of glabellar lines and crow's feet, respectively). Images from the treated areas were collected using Antera 3D® device at baseline, 4 weeks and 4 months after treatment, at both rest and maximum muscles contraction.Results: Improvements for both glabellar lines and crow's feet lines were detected with Digital Analysis of the Cutaneous Surface, further confirming the efficacy of Onabotulinum toxin A.
Conclusion:The digital evaluation tool proposed in this study is an objective and easy to use method for the assessment of glabellar lines and crow's feet lines improvements after the treatment with Onabotulinum toxin A.
Botulinum toxin type A treatment of crow's feet was able to improve STR. The Antera device and software are a valuable, objective, easy and reproducible method to assess the effects of the toxin.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.